Comparative efficacy of two types polysomnography in diagnosing and monitoring OSA patients at COVID-19 pandemic: a retrospective study.

Publication date: Sep 23, 2025

Sleep-related breathing disorders, including snoring and obstructive sleep apnea (OSA), impact on the quality of life and are linked to various comorbidities. We retrospectively analyzed thirty-seven dental medical records of patients aged 25-80 with snoring and OSA treated with a customized mandibular advancement device (MAD) with the gold-standard type-I polysomnography (PSG) and home test with type-IV (BIOLOGIX) for OSA monitoring in clinical practice during the COVID-19 pandemic, focusing on the clinical applicability. The metrics analyzed included the apnea-hypopnea index (AHI), oxygen desaturation index (ODI), heart rate, and oxygen saturation (SpO2). Statistical analysis revealed significant changes in four metrics and correlations between heart rate and ODI. Results suggest that type-IV PSG is a viable alternative for OSA monitoring, particularly during the COVID-19 pandemic when access to sleep labs was limited. The customized MAD effectively reduced AHI. Unlike type-I PSG, type-IV PSG has limited diagnostic; it does not provide comprehensive sleep metrics, which restricts its utility in complex cases. However, BIOLOGIX is a viable tool for monitoring patients in dental sleep medicine clinical practices. This study highlights the potential of type-IV PSG to enhance OSA management. Further research with larger samples is needed to refine its clinical application and improve predictive accuracy.

Semantics